CING Cingulate |
$4.39
-10.8% |
May 31, 2026
|
CTx-1301
Attention Deficit/Hyperactivity Disorder (ADHD)
|
NDA
|
10/14/2025 - PDUFA Date
Cingulate Inc. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target …
Full Summary
|
ARVN Arvinas |
$9.42
-4.6% |
June 5, 2026
|
Vepdegestrant
For ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
|
NDA
|
8/8/2025 - PDUFA Date
Arvinas, Inc. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action d…
Full Summary
|
ALLO Allogene Therapeutics |
$2.14
-8.2% |
H1 2026
|
Cemacabtagene Ansegedleucel
For Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
|
|
6/20/2024 - Enrollment Update
Allogene Therapeutics Inc announced that ALPHA3 Expected to Complete Enrollment in 1H 2026
Full Summary
|
AKRO Akero Therapeutics |
$54.65
+0.2% |
H1 2026
|
Efruxifermin
Non-alcoholic steatohepatitis (NASH)
|
|
1/13/2025 - Data
Akero Therapeutics, Inc announced that Data from SYNCHRONY Real-World study anticipated in the first…
Full Summary
|
KYMR Kymera Therapeutics |
$84.50
-1.3% |
H1 2026
|
KT-474
Hidradenitis Suppurativa or Atopic Dermatitis (AD)
|
Phase 2b
|
1/14/2025 - Provided Update
Kymera Therapeutics announced that KT-474/SAR444656 (IRAK4) Phase 2b dose-ranging studies in hidrade…
Full Summary
|
XFOR X4 Pharmaceuticals |
$4.00
-5.4% |
H1 2026
|
Mavorixafor
In people diagnosed with idiopathic, cyclic, or congenital neutropenia.
|
MAA
|
1/24/2025 - Provided Update
X4 Pharmaceuticals announced that Decision on MAA expected in 1H 2026
Full Summary
|
MDWD MediWound |
$16.80
+3.4% |
H1 2026
|
EscharEx
Chronic Wounds
|
|
2/12/2025 - Provided Update
MediWound Ltd announced that Interim analysis planned after 65% of patients complete treatment, expe…
Full Summary
|
QTTB Q32 Bio |
$6.25
+5.2% |
H1 2026
|
Bempikibart
For Severe Alopecia Areata
|
|
4/16/2025 - Data readout
Q32 Bio Inc. announced that SIGNAL-AA Part B topline data readout on-track for 1H'26 --
Full Summary
|
BCTX Briacell Therap |
$4.05
-3.1% |
H1 2026
|
Bria-IMT
Metastatic breast cancer (breast cancer that has spread beyond the breast)
|
Phase 3
|
4/22/2025 - Top-line data
BriaCell anticipates top line data as early as H1-2026.
Full Summary
|
ZYME Zymeworks |
$23.96
-2.5% |
H1 2026
|
ZW209
For small cell lung cancer
|
IND
|
4/25/2025 - IND Filing
Zymeworks announced that Novel T cell engager ZW209 demonstrates durable activity in small cell lung…
Full Summary
|
CNTB Connect Biopharma |
$2.48
+1.2% |
H1 2026
|
Rademikibart
For Moderate-To-Severe Atopic Dermatitis
|
|
5/14/2025 - Top-line data
Connect Biopharma Holdings Limited Expect to report topline data from the Seabreeze STAT COPD study …
Full Summary
|
GLUE Monte Rosa Therapeutics |
$18.68
-1.5% |
H1 2026
|
MRT-8102
For the treatment of inflammatory diseases
|
Phase 1
|
6/10/2025 - Results
Monte Rosa Therapeutics, Inc. announced that MRT-8102 Phase 1 clinical results, including data on s…
Full Summary
|
LPCN Lipocine |
$2.33
+0.4% |
Q2 2026
|
LPCN 1154
Postpartum depression (PPD)
|
Phase 3
|
6/26/2025 - Top-line results
Lipocine Inc announced that Phase 3 Top Line Results Expected Q2 2026
Full Summary
|
FLNA Cassava Sciences |
$1.24
+0.8% |
H1 2026
|
Simufilam
Alzheimer's Disease
|
|
8/4/2025 - Clinical Study
Cassava Sciences, Inc. announced that First clinical study for simufilam in TSC-related epilepsy ex…
Full Summary
|
NTLA Intellia Therapeutics |
$13.09
-8.3% |
H1 2026
|
onvo-z
hereditary angioedema
|
|
9/18/2025 - Top-line data
Intellia Therapeutics, announced that Topline data are expected in the first half of 2026.
Full Summary
|
CRMD CorMedix |
$7.93
+5.7% |
Q2 2026
|
REZZAYO
in the prevention of Candida, Aspergillus, and Pneumocystis infection in patients undergoing allogeneic blood and marrow transplantation (BMT).
|
|
9/29/2025 - Top-line results
CorMedix Inc. announced that Topline Results from ReSPECT Study Expected in 2Q 2026
Full Summary
|
LPCN Lipocine |
$2.33
+0.4% |
Q2 2026
|
LPCN 1154
Postpartum depression (PPD)
|
|
9/30/2025 - Top-line results
Lipocine Inc announced that The study is progressing on track with one-third of planned patients ra…
Full Summary
|
RGNX REGENXBIO |
$6.24
-37.8% |
Q2 2026
|
RGX-202
Duchenne Muscular Dystrophy
|
|
10/30/2025 - Top-line data
REGENXBIO Inc. announced that Topline pivotal data now expected in early Q2 2026
Full Summary
|
RGNX REGENXBIO |
$6.24
-37.8% |
H1 2026
|
RGX-202
Duchenne Muscular Dystrophy
|
BLA
|
10/30/2025 - BLA Filing
REGENXBIO Inc. announced that BLA submission in mid-2026
Full Summary
|
LPCN Lipocine |
$2.33
+0.4% |
Q2 2026
|
LPCN 1154
Postpartum depression (PPD)
|
|
11/18/2025 - Top-line results
Lipocine Inc announced that Topline results are on track for the second quarter of 2026
Full Summary
|
RAPP Rapport Therapeutics |
$37.95
-0.3% |
Q2 2026
|
RAP-219
For CNS Disorders
|
Phase 3
|
1/7/2026 - Study Initiation
Rapport Therapeutics, Inc announced plans to initiate its Phase 3 program for RAP-219 in FOS in th…
Full Summary
|
SRPT Sarepta Therapeutics |
$18.68
-0.8% |
Q2 2026
|
SRP-1005-101
Treatment for Huntington's Disease
|
|
1/7/2026 - Provided Update
Sarepta Therapeutics, Inc announced that Pending approval, Sarepta expects to initiate this first-i…
Full Summary
|
SCNX Scienture |
$0.41
+0.5% |
Q2 2026
|
Arbli
for hypertension
|
|
2/3/2026 - Provided Update
SCIENTURE HOLDINGS, INC provided a commercial update on ARBLI™ (losartan potassium) oral suspension,…
Full Summary
|
SCPH scPharmaceuticals |
$5.67
|
July 26, 2026
|
FUROSCIX
Decompensated heart failure
|
supplemental New Drug Application (sNDA)
|
12/1/2025 - PDUFA Date
MannKind Corporation The application has been assigned a Prescription Drug User Fee Act (PDUFA) targ…
Full Summary
|
LNTH Lantheus |
$96.67
+0.2% |
August 13, 2026
|
MK-6240
PET Imaging Agent Targeting Tau in Alzheimer's Disease
|
NDA
|
10/28/2025 - PDUFA Date
Lantheus Holdings, Inc. announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) tar…
Full Summary
|
MRK Merck & Co., Inc. |
$113.21
-0.2% |
August 17, 2026
|
KEYTRUDA QLEX™
Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
|
supplemental New Drug Application (sNDA) Priority Review
|
4/20/2026 - PDUFA Date
Merck announced that The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date o…
Full Summary
|
SVRA Savara |
$5.27
|
August 22, 2026
|
MOLBREEVI
Treatment for aPAP.
|
BLA
|
2/20/2026 - PDUFA Date
Savara Inc announced that The FDA granted Priority Review with a PDUFA action date of August 22, 202…
Full Summary
|
JAZZ Jazz Pharmaceuticals |
$231.05
-0.6% |
August 25, 2026
|
Ziihera
For the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
|
supplemental New Drug Application (sNDA)
|
4/27/2026 - PDUFA Date
Jazz Pharmaceuticals plc announced that The FDA has set a PDUFA target action date of August 25, 20…
Full Summary
|
GILD Gilead Sciences |
$132.06
-0.7% |
August 27, 2026
|
BIC/LEN
treatment of HIV
|
NDA
|
4/29/2026 - PDUFA Date
Gilead Sciences, Inc announced that The FDA has granted priority review of the application and assi…
Full Summary
|
NUVL Nuvalent |
$104.41
-0.8% |
September 18, 2026
|
zidesamtinib
ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib
|
NDA
|
11/19/2025 - PDUFA Date
Nuvalent, Inc. announced that FDA assigns PDUFA target action date of September 18, 2026
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$25.80
-2.5% |
September 19, 2026
|
UX111
For Sanfilippo syndrome type A (MPS IIIA)
|
BLA
|
4/2/2026 - PDUFA Date
Ultragenyx Pharmaceutical announced that The FDA set a Prescription Drug User Fee Act (PDUFA) action…
Full Summary
|
IONS Ionis Pharmaceuticals |
$75.68
-2.5% |
September 22, 2026
|
Zilganersen
for the treatment of children and adults Alexander disease (AxD).
|
NDA Priority Review
|
3/23/2026 - PDUFA Date
Ionis Pharmaceuticals, Inc announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) …
Full Summary
|
ALMS Alumis |
$24.63
-0.9% |
Q3 2026
|
ESK-001
In Moderate-to-Severe Plaque Psoriasis
|
|
7/24/2025 - Topline Readout
Alumis Inc. announced that Topline Readout Expected in Q3 2026
Full Summary
|
SLN Silence Therapeutics |
$7.13
+2.1% |
Q3 2026
|
divesiran
In patients with polycythemia vera
|
Phase 2
|
10/23/2025 - Top-line results
Silence Therapeutics plc announced that Initial topline results from the SANRECO Phase 2 study are …
Full Summary
|
ROIV Roivant Sciences |
$29.50
+1.0% |
Q3 2026
|
Brepocitinib
Systemic Lupus Erythematosus
|
NDA
|
3/3/2026 - PDUFA Date
Priovant Therapeutics announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) …
Full Summary
|
IMMX Immix Biopharma |
$10.10
-3.7% |
Q3 2026
|
NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.
|
|
3/30/2026 - Top-line results
Immix Biopharma, Inc. announced that NEXICART-2 enrollment is complete, meeting Company guidance, w…
Full Summary
|
QURE uniQure |
$27.75
-4.9% |
Q3 2026
|
AMT-130
Huntington's Disease
|
|
4/30/2026 - Provided Update
uniQure N.V. announced the Company held a Pre-Submission Meeting with the United Kingdom's (UK) Med…
Full Summary
|
ALLR Allarity Therapeutics |
$1.51
-1.9% |
Q3 2026
|
Stenoparib
For ovarian cancer (AOC)
|
|
5/5/2026 - Provided Update
Allarity Therapeutics, Inc. announced that its active pharmaceutical ingredient (API) manufacturing …
Full Summary
|
MRK Merck & Co., Inc. |
$113.21
-0.2% |
October 10, 2026
|
I-DXd
In patients with pretreated extensive-stage small cell lung cancer (ES-SCLC).
|
BLA
|
4/13/2026 - PDUFA Date
Daiichi Sankyo and Merck announced that The Prescription Drug User Fee Act (PDUFA) date, the FDA …
Full Summary
|
SVRA Savara |
$5.27
|
November 22, 2026
|
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
4/15/2026 - PDUFA Date
Savara Inc. announced Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Mo…
Full Summary
|
COGT Cogent Biosciences |
$34.19
-0.3% |
December 30, 2026
|
bezuclastinib
In patients with non-advanced systemic mastocytosis
|
NDA
|
3/16/2026 - PDUFA Date
Cogent Biosciences, Inc announced that the Prescription Drug User Fee Act (PDUFA) target action date…
Full Summary
|
ANNX Annexon |
$5.37
-1.5% |
H2 2026
|
ANX007
Geographic Atrophy
|
|
9/9/2024 - Data
Annexon, Inc. announced that ARCHER II Phase 3 Pivotal Program in GA Underway with Data Expected Se…
Full Summary
|
ANNX Annexon |
$5.37
-1.5% |
H2 2026
|
ANX007
Geographic Atrophy
|
Phase 3
|
12/5/2024 - Provided Update
Annexon, Inc. Pivotal Phase 3 ARCHER II in GA Actively Enrolling with Data Expected Second Half 2026
Full Summary
|
KNSA Kiniksa Pharmaceuticals International |
$58.54
-1.0% |
H2 2026
|
KPL-387
In recurrent pericarditis
|
Phase 2
|
6/5/2025 - Data
Kiniksa Pharmaceuticals International announced that Phase 2 data expected in 2H 2026
Full Summary
|
RGNX REGENXBIO |
$6.24
-37.8% |
Q4 2026
|
surabgene lomparvovec
for Wet AMD
|
|
10/6/2025 - Top-line data
REGENXBIO Inc. announced that Topline pivotal data expected in Q4 2026
Full Summary
|
ACET Adicet Bio |
$8.41
+4.2% |
H2 2026
|
ADI-001
B cell non-Hodgkin's lymphoma (NHL)
|
Phase 1
|
10/16/2025 - Preclinical Data
Adicet Bio, Inc. announced that Preliminary clinical data from the Phase 1 trial expected in 2H/2026
Full Summary
|
VRCA Verrica Pharmaceuticals |
$6.95
-5.7% |
Q4 2026
|
YCANTH™ (cantharidin)
For molluscum contagiosum, which is primarily a pediatric disease.
|
|
10/20/2025 - Provided Update
Verrica is initiating activities to support this regulatory submission, which could be filed as earl…
Full Summary
|
MIRM Mirum Pharmaceuticals |
$111.39
+2.0% |
Q4 2026
|
Maralixibat
Alagille Syndrome
|
|
3/16/2026 - Top-line data
Mirum Pharmaceuticals, Inc. announced that the Topline data expected in Q4 2026
Full Summary
|
ACRS Aclaris Therapeutics |
$4.80
-5.7% |
Q4 2026
|
ATI-045
In Atopic Dermatitis (AD)
|
|
3/18/2026 - Top-line results
Aclaris Therapeutics, Inc. announced that the Top line results are expected in the fourth quarter o…
Full Summary
|
ENTA Enanta Pharmaceuticals |
$13.81
-1.6% |
Q4 2026
|
EDP-978
Treatment of Urticaria
|
|
4/13/2026 - Top-line data
Enanta Pharmaceuticals, Inc announced that the Topline Data Expected in Q4 2026
Full Summary
|
BBIO BridgeBio Pharma |
$69.66
+1.5% |
H2 2026
|
BBO-11818
Potent panKRAS Inhibitor
|
|
4/20/2026 - Clinical Data
BridgeBio Oncology Therapeutics, Inc. announced that the Updated Phase 1 clinical data are expected …
Full Summary
|
NUVB Nuvation Bio |
$4.71
-1.6% |
January 4, 2027
|
IBTROZI
In Advanced ROS1-Positive Non-Small Cell Lung Cancer
|
supplemental New Drug Application (sNDA)
|
5/6/2026 - PDUFA Date
Nuvation Bio Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted a sup…
Full Summary
|
CGEM Cullinan Therapeutics |
$16.15
-1.1% |
February 27, 2027
|
zipalertinib
For patients with heavily pre-treated EGFR ex20ins mutation NSCLC
|
NDA
|
4/28/2026 - PDUFA Date
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, announced that The…
Full Summary
|
PMVP PMV Pharmaceuticals |
$1.33
+3.1% |
Q1 2027
|
rezatapopt
in patients with advanced solid tumors
|
NDA
|
10/24/2025 - NDA Filing
PMV Pharmaceuticals, announced that
Full Summary
|
NBTX Nanobiotix |
$55.07
+5.8% |
H1 2027
|
NANORAY-312
head and neck squamous cell cancers.
|
|
10/24/2025 - Interim Data
Nanobiotix estimates that NANORAY-312 interim data will be analyzed and reported, after both the req…
Full Summary
|
LBRX LB Pharmaceuticals |
$31.41
-2.8% |
H2 2027
|
LB-102
In Patients With Bipolar Depression
|
|
3/25/2026 - Top-line data
LB Pharmaceuticals Inc announced that the Topline data expected in 2H 2027
Full Summary
|
